Defending the Advantages of Advantage
This article was originally published in RPM Report
The Obama Administration has sunk its teeth into Medicare Advantage to fi nd cost savings in the federal budget. Pharma and biotech should align with health plans to defend the program.
You may also be interested in...
Medicare Advantage: Is It Strong Enough To Survive Obama Reform?
Medicare Advantage programs are in the crosshairs of Obama health care reform. The new president has singled out the full-service plans reconstituted under Part D as a major source for the down payment funds for comprehensive health care reform: well over a quarter of the funds for the new system would come from cuts in government payments to Medicare Advantage programs. The situation looks bad for MA plans, but it may be early to write them off. They are strong after five good years of growth.
Specialty Drug Tier: When Special Means Expensive
Medicare led the way to create a policy that’s just plain mean. Is there any way back?